Fintel reports that on October 24, 2023, Morgan Stanley maintained coverage of Nanostring Technologies (NASDAQ:NSTG) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 826.80% Upside
As of October 4, 2023, the average one-year price target for Nanostring Technologies is 13.11. The forecasts range from a low of 7.07 to a high of $25.20. The average price target represents an increase of 826.80% from its latest reported closing price of 1.42.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Nanostring Technologies is 178MM, an increase of 23.90%. The projected annual non-GAAP EPS is -2.16.
What is the Fund Sentiment?
There are 312 funds or institutions reporting positions in Nanostring Technologies. This is a decrease of 9 owner(s) or 2.80% in the last quarter. Average portfolio weight of all funds dedicated to NSTG is 0.07%, an increase of 8.33%. Total shares owned by institutions increased in the last three months by 5.63% to 51,855K shares. 
The put/call ratio of NSTG is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Polar Capital Holdings holds 3,975K shares representing 8.36% ownership of the company. In it's prior filing, the firm reported owning 4,000K shares, representing a decrease of 0.63%. The firm decreased its portfolio allocation in NSTG by 61.53% over the last quarter.
Blue Water Life Science Advisors holds 2,727K shares representing 5.74% ownership of the company.
Avidity Partners Management holds 2,700K shares representing 5.68% ownership of the company. In it's prior filing, the firm reported owning 2,217K shares, representing an increase of 17.90%. The firm decreased its portfolio allocation in NSTG by 47.57% over the last quarter.
D. E. Shaw holds 2,151K shares representing 4.52% ownership of the company. In it's prior filing, the firm reported owning 1,914K shares, representing an increase of 11.01%. The firm decreased its portfolio allocation in NSTG by 44.30% over the last quarter.
Prosight Management holds 2,000K shares representing 4.21% ownership of the company.
Nanostring Technologies Background Information
(This description is provided by the company.)
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 4,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx® Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
